Unknown

Dataset Information

0

A Nitrobenzoyl Sesquiterpenoid Insulicolide A Prevents Osteoclast Formation via Suppressing c-Fos-NFATc1 Signaling Pathway.


ABSTRACT: It is a viable strategy to inhibit osteoclast differentiation for the treatment of osteolytic diseases such as osteoporosis, rheumatoid arthritis and tumor bone metastases. Here we assessed the effects of insulicolide A, a natural nitrobenzoyl sesquiterpenoid derived from marine fungus, on receptor activator of nuclear factor-κB ligand (RANKL)-stimulated osteoclastogenesis in vitro and its protective effects on LPS-induced osteolysis mice model in vivo. The results demonstrated that insulicolide A inhibited osteoclastogenesis from 1 μM in vitro. Insulicolide A could prevent c-Fos and nuclear factor of activated T-cell cytoplasmic 1 (NFATc1) nuclear translocation and attenuate the expression levels of osteoclast-related genes and DC-STAMP during RANKL-stimulated osteoclastogenesis but have no effects on NF-κB and MAPKs. Insulicolide A can also protect the mice from LPS-induced osteolysis. Our research provides the first evidence that insulicolide A may inhibit osteoclastogenesis both in vitro and in vivo, and indicates that it may have potential for the treatment of osteoclast-related diseases.

SUBMITTER: Tan Y 

PROVIDER: S-EPMC8801808 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature

altmetric image

Publications

A Nitrobenzoyl Sesquiterpenoid Insulicolide A Prevents Osteoclast Formation <i>via</i> Suppressing c-Fos-NFATc1 Signaling Pathway.

Tan Yanhui Y   Ke Minhong M   Li Zhichao Z   Chen Yan Y   Zheng Jiehuang J   Wang Yiyuan Y   Zhou Xuefeng X   Huang Gang G   Li Xiaojuan X  

Frontiers in pharmacology 20220117


It is a viable strategy to inhibit osteoclast differentiation for the treatment of osteolytic diseases such as osteoporosis, rheumatoid arthritis and tumor bone metastases. Here we assessed the effects of insulicolide A, a natural nitrobenzoyl sesquiterpenoid derived from marine fungus, on receptor activator of nuclear factor-κB ligand (RANKL)-stimulated osteoclastogenesis <i>in vitro</i> and its protective effects on LPS-induced osteolysis mice model <i>in vivo</i>. The results demonstrated tha  ...[more]

Similar Datasets

| S-EPMC5788605 | biostudies-literature
| S-EPMC9061820 | biostudies-literature
| S-EPMC5099608 | biostudies-literature
| S-EPMC7643645 | biostudies-literature
| S-EPMC7294126 | biostudies-literature
| S-EPMC7076887 | biostudies-literature
| S-EPMC10460717 | biostudies-literature
| S-EPMC6949687 | biostudies-literature
| S-EPMC3851046 | biostudies-literature
| S-EPMC5709360 | biostudies-literature